4-Hydroxy-3-nitrobenzonitrile | CAS:3272-08-0

We serve 4-Hydroxy-3-nitrobenzonitrile CAS:3272-08-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Hydroxy-3-nitrobenzonitrile

Chemical Name:4-Hydroxy-3-nitrobenzonitrile
CAS.NO:3272-08-0
Synonyms:4-Hydroxy-3-nitrobenzonitrile
4-Hydroxy-3-nitro-benzonitrile
4-hydroxy-3-nitrobenzenecarbonitrile
2-Nitro-4-cyanophenol
3-nitro-4-hydroxybenzonitrile
4-Cyano-2-nitrophenol
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 288.9±30.0 °C at 760 mmHg
Melting Point 146-148 °C(lit.)
Molecular Formula C7H4N2O3
Molecular Weight 164.118
Flash Point 128.5±24.6 °C
 
Specification:
Appearance:Yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Febuxostat(CAS:144060-53-7).



Contact us for information like 4-Hydroxy-3-nitrobenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Cyano-2-nitrophenol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Hydroxy-3-nitrobenzonitrile Use and application,4-Cyano-2-nitrophenol technical grade,usp/ep/jp grade.


Related News: The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”2'-Deoxyguanosine-5'-triphosphate trisodium salt manufacturer It also said it would bar South Koreans from visiting China as tourists.Iodotrimethylsilane supplier It also said it would bar South Koreans from visiting China as tourists.butyl 2-[(2Z)-2-[2-oxo-3-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)carbamoyl]naphthalen-1-ylidene]hydrazinyl]benzoate vendor There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.